Open-label phase 2 trial demonstrates long-term overall survival benefits in advanced hepatocellular carcinoma, indicating potential for effective treatment.
Pembrolizumab continued to show durable response and manageable safety in participants with advanced HCC with or without prior systemic therapy, with long-term effects on OS lasting beyond 48 months in some participants despite receiving study treatment for ≤2 years.
No takes yet. Share an insight, caveat, or question.
Finn et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: